You are here: Industry Insights > FDA

News List

Fighting Against COVID-19: Summary of Key Products PharmaSources/Recollect
February 22, 2022
Since the outbreak of COVID-19 in 2019, many kinds of COVID-19 vaccines, COVID-19 preventive drugs and COVID-19 therapeutic drugs have been approved worldwide.
AbbVie's performance in 2021: a new high in total revenue, with the sales volumes of Hu-mi-ra topping USD 20 billion PharmaSources/Yi
February 22, 2022
On February 2, AbbVie announced its performance in the fourth quarter and full year of 2021, representing an annual revenue of USD 56.197 billion (+22.7%) and R&D investment of USD 7.084 billion (+8%).
An Introduction to FDA Clinical Investigator Training Course Lin Zhang
January 17, 2022
The U.S. Food and Drug Administration (FDA) held a Clinical Investigator Training Course or the CITC last month (12/7-8/2021). This course has been conducted for over ten years.
FDA changes Hepatitis C Devices Categorization SHEM OIRERE
December 17, 2021
To Support Global efforts to test and treat chronic hepatitis C has received a major boost from the Food and Drug Administration (FDA) after the US-based regulator issued a final order for the reclassification...
Electronic Drug Registration and Listing (eDRLS) Lin Zhang
December 02, 2021
Last month (October 13, 2021), the Food and Drug Administration (FDA) held a conference that is part of the CDER Small Business & Industry Assistance (SBIA) Regulatory Education for Industry (REdI) series.
Analysis on the Layout of Innovative Drugs in China and Globally PharmaSources/Zhulikou431
October 27, 2021
Recently, there is a saying in the pharmaceutical industry: not all innovative drugs have a future. This saying reminds me of the lyrics - wild lilies also have spring.
Advancing Generic Drug Development to Approval Lin Zhang
October 22, 2021
The FDA continuously works to change and improve their work, including the work done with generic drugs. Last month, September 21-22, 2021, the Food and Drug Administration (FDA) hosted a workshop...
ADUHELM: The First FDA Approved Therapy for Alzheimer’s Disease Since 2003 Lin Zhang
July 20, 2021
Aducanumab, known as ADUHELM, was co-developed by Biogen and Eisai and newly approved by the United States Food and Drug Administration (FDA) on June 7, 2021 (BLA 761178) under the provisions of accelerated approval regulations (21 CFR 601.41).
Pharmaceutical Companies Back to the Blue Ocean of AD in the Wake of Aduhelm's Approval PharmaSources/Yefenghong
July 20, 2021
On June 8, the FDA issued an accelerated approval to Biogen/Eisai's powdered protein antibody Aduhelm (generic name aducanumab) for the treatment of Alzheimer's disease (AD).
Good News in the Anti-AβAntibodies Field, Two Drugs were Successively Granted Breakthrough Drug Qualification by the FDA PharmaSources/Dopine
July 13, 2021
Two AD drugs have been granted BTD by the FDA recently, namely Eisai/Biogen's Lecanemab (BAN2401) and Eli Lilly's Donanemab.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 366 367 Next page